DK2924047T3 - Vaccinebærer - Google Patents

Vaccinebærer Download PDF

Info

Publication number
DK2924047T3
DK2924047T3 DK15161237.1T DK15161237T DK2924047T3 DK 2924047 T3 DK2924047 T3 DK 2924047T3 DK 15161237 T DK15161237 T DK 15161237T DK 2924047 T3 DK2924047 T3 DK 2924047T3
Authority
DK
Denmark
Prior art keywords
ala
glu
lys
leu
asp
Prior art date
Application number
DK15161237.1T
Other languages
English (en)
Inventor
Rudolf Valenta
Margarete Focke-Tejkl
Birgit Linhart
Susanne Vrtala
Peter Valent
Renate Reininger
Susanne Spitzauer
Ines Swoboda
Hage Marianne Van
Hans Grönlund
Johanna Tinhofer
Kerstin Westritschnig
Theresia Popow-Kraupp
Original Assignee
Biomay Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomay Ag filed Critical Biomay Ag
Application granted granted Critical
Publication of DK2924047T3 publication Critical patent/DK2924047T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • A61K39/36Allergens from pollen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32711Rhinovirus
    • C12N2770/32734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (10)

1. A Hypoallergent molekyle, der er afledt af Phl p 5 og består af amino-syresekvens GAASNKAFAEGLSGEPKGAAESSSKAALTSK, ADLGYGPAT-PAAPAAGYTPATPAAPAEAAPAGK eller TVATAPEVKYTVFETALKKAI-TAMSEAQKAAK.
2. Hypoallergent fusionsprotein omfattende et hypoallergent molekyle ifølge krav 1 fusioneret på mindst et viruscapsidprotein, hvor det hypoallergene molekyle er fusioneret på N-terminus og/eller C-terminus af det mindst ene viruscapsidprotein.
3. Hypoallergent protein ifølge krav 2, kendetegnet ved, at det mindst ene viruscapsidprotein er afledt fra en human patogen virus.
4. Hypoallergent protein ifølge krav 3, kendetegnet ved, at den humane patogene virus er en virus af familien picornaviridae.
5. Hypoallergent protein ifølge krav 4, kendetegnet ved, at virussen af familien picornaviridae er af arten af rhinovira, fortrinsvis af arten af humane rhino-vira, især human rhinovirus 89 eller 14.
6. Nukleinsyremolekyle, der koder for et hypoallergent molekyle ifølge krav 1 eller et hypoallergent fusionsprotein ifølge et hvilket som helst af kravene 2 til 5.
7. Vektor omfattende et nukleinsyremolekyle ifølge krav 6, hvor vektoren med hensyn til en nukleinsyre, der koder for Phl p5, består af en nukleinsyrese-kvens, der koder for det hypoallergene molekyle bestående af aminosyrese-kvensen defineret i krav 1.
8. Vaccineformulering omfattende et hypoallergent molekyle ifølge krav 1 eller et hypoallergent fusionsprotein ifølge et hvilket som helst af kravene 2 til 5.
9. Formulering ifølge krav 8, kendetegnet ved, at formuleringen yderligere omfatter mindst en adjuvans, et farmaceutisk acceptabelt hjælpestof og/eller konserveringsmiddel.
10. Hypoallergent molekyle ifølge krav 1 eller hypoallergent fusionsprotein ifølge et hvilket som helst af kravene 2 til 5 til anvendelse ved behandling eller forebyggelse af en allergi hos et menneske eller et dyr.
DK15161237.1T 2006-06-09 2007-06-11 Vaccinebærer DK2924047T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0099406A AT503690A1 (de) 2006-06-09 2006-06-09 Hypoallergene moleküle
EP07718492.7A EP2035457B1 (en) 2006-06-09 2007-06-11 Vaccine carrier

Publications (1)

Publication Number Publication Date
DK2924047T3 true DK2924047T3 (da) 2018-12-03

Family

ID=38650124

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15161237.1T DK2924047T3 (da) 2006-06-09 2007-06-11 Vaccinebærer
DK07718492.7T DK2035457T3 (da) 2006-06-09 2007-06-11 Vaccinebærer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07718492.7T DK2035457T3 (da) 2006-06-09 2007-06-11 Vaccinebærer

Country Status (14)

Country Link
US (2) US9296828B2 (da)
EP (2) EP2924047B1 (da)
JP (3) JP5399895B2 (da)
CN (3) CN101466738A (da)
AT (1) AT503690A1 (da)
AU (1) AU2007257308B2 (da)
BR (1) BR122019004393B1 (da)
CA (1) CA2657971C (da)
DK (2) DK2924047T3 (da)
ES (2) ES2541311T3 (da)
PL (1) PL2035457T3 (da)
PT (1) PT2035457E (da)
RU (1) RU2486206C2 (da)
WO (1) WO2007140505A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2190473T1 (sl) * 2007-08-15 2013-05-31 Circassia Limited Peptid z zmanjšano tvorbo dimerov
SI2153841T2 (sl) * 2008-08-15 2016-02-29 Circassia Limited Cepivo, ki obsega peptide Amb a 1, za uporabo pri zdravljenju alergije na ambrozijo
WO2010076583A1 (en) * 2008-12-30 2010-07-08 Kaw Yan Chua A variant of mite allergen and uses thereof
CO6260019A1 (es) 2009-01-30 2011-03-22 Fundacion Universidad Del Norte Metodo y composicion inmunoquimica para la deteccion de alergenos de acaros usando anticuerpos policlonales igy
AU2013202362B2 (en) * 2009-02-05 2015-09-17 Circassia Limited Grass Peptides for Vaccine
CN103784952B (zh) * 2009-02-05 2016-08-17 切尔卡西亚有限公司 用于疫苗的草肽
EP2316481A1 (en) * 2009-10-30 2011-05-04 Biomay Ag Pharmaceutical composition for the treatment and prevention of a rhinovirus infection
CA2838217C (en) * 2011-06-09 2022-11-01 Biomay Ag Peptide carrier fusion proteins as allergy vaccines
WO2013001362A2 (en) * 2011-06-27 2013-01-03 Anergis S.A. Contiguous overlapping peptides for treatment of ragweed pollen allergy
EP2543725A1 (en) * 2011-07-08 2013-01-09 Biomay Ag Polysaccharide lyases
JO3820B1 (ar) * 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
GB201209868D0 (en) * 2012-06-01 2012-07-18 Circassia Ltd Alternaria peptides
US9163069B2 (en) 2012-09-20 2015-10-20 Universidad De Cartagena Fusion proteins representing different allergens and a vaccine against allergy to mites
JP2014231500A (ja) * 2013-05-29 2014-12-11 元晴 植原 シラカンバ花粉症の免疫療法に用いるペプチド混合物
WO2015027154A2 (en) 2013-08-23 2015-02-26 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
WO2017004561A1 (en) * 2015-07-01 2017-01-05 Alk-Abelló A/S Peptide combinations and uses thereof for treating grass allergy
US11352417B2 (en) 2016-12-22 2022-06-07 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
US11408895B1 (en) 2018-04-09 2022-08-09 Hob Biotech Group Corp., Ltd. Allergen characterization, potent allergen product formulation, comprehensive allergen reagent, and allergy assay
EP3569612A1 (en) * 2018-05-18 2019-11-20 Biomay Ag Treatment and prevention of house dust mite allergies
RU2761431C9 (ru) 2020-10-26 2022-04-18 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Рекомбинантный полипептид на основе аллергена пыльцы березы и аллергена яблока в качестве вакцины от аллергии

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8821077D0 (en) 1988-09-08 1988-10-05 Wellcome Found Peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6019972A (en) * 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
IL103456A (en) * 1991-10-16 2006-06-11 Merck Patent Gmbh Isolated peptides having t-cell stimulating activity
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AT401937B (de) * 1993-04-01 1996-12-27 Biomay Prod & Handel Rekombinantes lieschgras pollen allergen phl p ii
JPH09501043A (ja) * 1993-04-14 1997-02-04 イミュロジク ファーマスーティカル コーポレイション Dermatophagoides(室内塵ダニ)由来の主要アレルゲンのt細胞エピトープ
JPH09512014A (ja) * 1994-04-14 1997-12-02 イミユロジク・フアーマシユーチカル・コーポレーシヨン ダニアレルギー治療用の医薬ペプチド組成物
SE9402089D0 (sv) * 1994-06-14 1994-06-14 Rudolf Valenta Recombinant allergen, fragments thereof, corresponding recombinant DNA molecules, vectors and hosts containing the DNA molecules, diagnostic and therapeutic uses of said allergens and fragments
US6572859B1 (en) * 1999-10-29 2003-06-03 Pharmacia Diagnostics Ab Non-anaphylactic forms of grass pollen Phl p 6 allergen and their use
US20030166518A1 (en) * 2000-01-13 2003-09-04 Beardslee Thomas A. Method for allergen characterization
DE60137230D1 (de) * 2000-07-06 2009-02-12 Univ Georgetown Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
ES2209563B1 (es) 2000-07-28 2005-10-01 Universidad Complutense De Madrid Produccion en la levadurapipchia pastoris y sistema de purificacion del alergeno recombinante de olea europaea ole e 1 para uso en diagnosis y tratamiento de alergias.
ATE414773T1 (de) * 2000-11-16 2008-12-15 Alk Abello As Mutante allergene
EP1221317A1 (en) * 2000-12-28 2002-07-10 SHAN-Beteiligungsgesellschaft m.b.H. Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
PL206709B1 (pl) * 2002-02-27 2010-09-30 Merck Patent Gmbh Sposób wytwarzania i sposób obniżania aktywności IgE głównego hipoalergicznego alergenu pyłku brzozy rBet v 1, główny hipoalergiczny alergen pyłku brzozy rBet v 1uzyskiwany takim sposobem i jego zastosowanie jako leku oraz kompozycja farmaceutyczna zawierająca taki główny alergen
CA2490866A1 (en) * 2002-06-26 2004-01-08 Advanced Bionutrition Corporation Viruses and virus-like particles for multiple antigen and target display
BR0312474A (pt) 2002-07-05 2005-04-26 Denis Leclerc Partìcula viral adjuvante
EP1440979B1 (en) 2003-01-21 2005-10-19 BIOMAY Produktions- und Handels- Aktiengesellschaft Process for the preparation of hypoallergenic mosaic proteins
GB0308988D0 (en) * 2003-04-17 2003-05-28 Univ Singapore Molecule
JP4782671B2 (ja) * 2003-06-04 2011-09-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 低減したアレルギー誘発性および保持されたT細胞反応性を有するPhlp5a誘導体
US20050053615A1 (en) * 2003-07-16 2005-03-10 Best Elaine A. Variants of mite group 1 allergens for the treatment of house dust mite allergy
DE10351471A1 (de) * 2003-11-04 2005-06-09 Ursula Prof. Dr. Wiedermann-Schmidt Polyvalente Allergievakzine
MXPA06006221A (es) * 2003-12-01 2008-02-13 Dow Global Technologies Inc Produccion de particula tipo virus icosaedrico recombinante en organismos del genero pseudomonas.
ITRM20040103A1 (it) * 2004-02-27 2004-05-27 Consiglio Nazionale Ricerche Proteine di fusione comprendenti allergeni della famiglia delle ns-ltps, loro usi e composizioni farmaceutiche che le comprendono.
EP1720990A4 (en) * 2004-02-27 2008-04-30 Dow Global Technologies Inc HIGHLY EFFICIENT PEPTIDE PRODUCTION IN PLANT CELLS
US20060088549A1 (en) * 2004-07-08 2006-04-27 Arnold Gail F Chimeric virus vaccine
DE102004035337A1 (de) 2004-07-21 2006-03-16 Merck Patent Gmbh Varianten der Gruppe 1-Allergene aus Poaceae mit reduzierter Allergenität und erhaltener T-Zellreaktivität
AU2005286475A1 (en) * 2004-09-21 2006-03-30 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
AT501101B1 (de) * 2004-12-02 2008-01-15 Biomay Ag Protein-allergen-derivat
CA2599218C (en) * 2005-03-18 2015-08-11 Cytos Biotechnology Ag Cat allergen conjugates and uses thereof
EP2228656B1 (en) * 2005-09-15 2013-10-23 Alk-Abelló A/S Quantification of allergens

Also Published As

Publication number Publication date
AU2007257308B2 (en) 2013-06-06
EP2035457B1 (en) 2015-04-01
CN101466738A (zh) 2009-06-24
JP2014087341A (ja) 2014-05-15
AT503690A1 (de) 2007-12-15
US9296828B2 (en) 2016-03-29
EP2924047A1 (en) 2015-09-30
US20160257722A1 (en) 2016-09-08
WO2007140505A2 (en) 2007-12-13
CN103319602A (zh) 2013-09-25
US20090324501A1 (en) 2009-12-31
PT2035457E (pt) 2015-07-28
JP2009539354A (ja) 2009-11-19
CN103319602B (zh) 2016-09-07
BRPI0712421A2 (pt) 2012-06-19
JP5399895B2 (ja) 2014-01-29
ES2698525T3 (es) 2019-02-05
JP2014064573A (ja) 2014-04-17
RU2486206C2 (ru) 2013-06-27
CA2657971C (en) 2018-01-23
RU2008152045A (ru) 2010-07-20
EP2924047B1 (en) 2018-08-22
EP2035457A2 (en) 2009-03-18
CN103319601A (zh) 2013-09-25
AU2007257308A1 (en) 2007-12-13
DK2035457T3 (da) 2015-06-15
CA2657971A1 (en) 2007-12-13
BR122019004393B1 (pt) 2023-10-17
PL2035457T3 (pl) 2015-10-30
WO2007140505A3 (en) 2008-03-20
ES2541311T3 (es) 2015-07-17

Similar Documents

Publication Publication Date Title
DK2924047T3 (da) Vaccinebærer
US11376320B2 (en) Immunogenic and vaccine compositions against SARS-CoV-2
DK2717910T3 (da) Peptidbærerfusionsproteiner som allergivacciner
TWI620574B (zh) 口蹄疫合成胜肽緊急疫苗
CN113454102A (zh) 非洲猪瘟疫苗
CN106794236B (zh) A群链球菌疫苗
JP2013520487A (ja) 免疫原性タンパク質および組成物
WO2022003119A1 (en) Cross-reactive coronavirus vaccine
CN109923125B (zh) 免疫原性组合物
US10117923B2 (en) Production of an immunogen using a plant virus
US20210393768A1 (en) Compositions and methods for preventing and treating virus infection
WO2022207645A1 (en) Sars-cov-2 subunit vaccine
RU2689552C2 (ru) Новая иммунотерапевтическая композиция и ее применения
US20240299528A1 (en) A dna plasmid sars-corona virus-2/covid-19 vaccine
EP2987502B1 (en) Peptide adjuvants
EP4138901A1 (en) Compositions and methods for inducing immune responses against class i fusion protein viruses
TWI605056B (zh) 用於治療艱難梭狀芽孢桿菌(Clostridium difficile)相關疾病之組成物及方法
WO2015077442A2 (en) Grass pollen immunogens and methods and uses for immune response modulation
RU2775621C2 (ru) Иммуногенный пептид против стрептококков группы а
WO2023081861A1 (en) Enhanced expression via autotransporters
AU2014352986A1 (en) Pan pollen immunogens and methods and uses thereof for immune response modulation
AU2013222052B2 (en) Vaccine carrier
CN117957017A (zh) 包含重组重叠肽和天然蛋白质的疫苗制剂
AU2023208227A1 (en) Chimeric polypeptides
JP2008504004A (ja) 穀物からの4群主要アレルゲンのdna配列および組換え製剤